140 related articles for article (PubMed ID: 7268693)
21. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues.
Morinelli TA; Niewiarowski S; Kornecki E; Figures WR; Wachtfogel Y; Colman RW
Blood; 1983 Jan; 61(1):41-9. PubMed ID: 6293626
[No Abstract] [Full Text] [Related]
22. Differential ability of agonists to express distinct pools of fibrinogen (GpIIb/IIIa) receptors which can mediate the aggregation of human platelets.
Watts IS; Keery RJ; Lumley P
Thromb Haemost; 1989 Nov; 62(3):955-61. PubMed ID: 2512682
[TBL] [Abstract][Full Text] [Related]
23. Identification of platelet inhibitor present in the melon (Cucurbitacea cucumis melo).
Altman R; Rouvier J; Weisenberger H
Thromb Haemost; 1985 Jun; 53(3):312-3. PubMed ID: 3931281
[TBL] [Abstract][Full Text] [Related]
24. Beta-lactam antibiotic-induced platelet dysfunction: evidence for irreversible inhibition of platelet activation in vitro and in vivo after prolonged exposure to penicillin.
Burroughs SF; Johnson GJ
Blood; 1990 Apr; 75(7):1473-80. PubMed ID: 2180496
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
27. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
Heinroth I; Block HU; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
[TBL] [Abstract][Full Text] [Related]
28. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
29. Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis.
Anwer K; Gabis J; Romstedt K; Gojer C; Huzoor-Akbar
Life Sci; 1985 Jul; 37(1):63-70. PubMed ID: 3925267
[TBL] [Abstract][Full Text] [Related]
30. Hydrogen peroxide has a role in the aggregation of human platelets.
Del Principe D; Menichelli A; De Matteis W; Di Corpo ML; Di Giulio S; Finazzi-Agro A
FEBS Lett; 1985 Jun; 185(1):142-6. PubMed ID: 3996592
[TBL] [Abstract][Full Text] [Related]
31. Arachidonate is an antagonist of platelet activation by the endoperoxide analog U46619.
Huang EM; Detwiler TC
Biochim Biophys Acta; 1982 Apr; 715(2):246-9. PubMed ID: 6803846
[No Abstract] [Full Text] [Related]
32. The potentiation of phorbol ester-induced aggregation of human platelets by the prostaglandin endoperoxide analogue, U46619.
Edwards MC; Williamson EM; Evans FJ
J Pharm Pharmacol; 1987 May; 39(5):370-7. PubMed ID: 2886585
[TBL] [Abstract][Full Text] [Related]
33. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets.
di Minno G; Bertelé V; Bianchi L; Barbieri B; Cerletti C; Dejana E; de Gaetano G; Silver MJ
Thromb Haemost; 1981 Apr; 45(2):103-6. PubMed ID: 6266066
[TBL] [Abstract][Full Text] [Related]
34. Stereoselective inhibition of prostaglandin-induced calcium release from platelet membranes by trimetoquinol.
Mayo JR; Miller DD; Feller DR
Biochem Pharmacol; 1983 Jun; 32(12):1952-5. PubMed ID: 6882470
[No Abstract] [Full Text] [Related]
35. Effect of platelet agonists on airway reactivity and intrathoracic platelet accumulation.
Robertson DN; Page CP
Br J Pharmacol; 1987 Sep; 92(1):105-11. PubMed ID: 3664082
[TBL] [Abstract][Full Text] [Related]
36. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
[No Abstract] [Full Text] [Related]
37. Comparative antiaggregatory activity in human platelets of a benzopyranone aci-reductone, clofibric acid, and a 2,3-dihydrobenzofuran analogue.
Witiak DT; Kim SK; Romstedt K; Newman HA; Feller DR
J Med Chem; 1986 Nov; 29(11):2170-4. PubMed ID: 3097315
[TBL] [Abstract][Full Text] [Related]
38. Functional and morphological studies on blood platelets in a thrombasthenic horse.
Sutherland RJ; Cambridge H; Bolton JR
Aust Vet J; 1989 Nov; 66(11):366-70. PubMed ID: 2515843
[TBL] [Abstract][Full Text] [Related]
39. Role of ADP in platelet aggregation and fibrinogen binding induced by prostaglandin endoperoxides: studies in a patient with a selective defect of ADP-induced platelet aggregation.
Cattaneo M; Randi AM; Canciani MT; Lecchi A; Mannuci PM
Prog Clin Biol Res; 1988; 283():279-83. PubMed ID: 3211954
[No Abstract] [Full Text] [Related]
40. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement.
Kobune K; Inoue M; Morikawa M; Tsuboi M; Takanami Y; Iwane Y; Kudo T
Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):153-65. PubMed ID: 1811279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
